Compass Therapeutics (CMPX) to Release Quarterly Earnings on Thursday

Compass Therapeutics (NASDAQ:CMPX) is expected to issue its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:00 AM ET.

Compass Therapeutics Stock Performance

Shares of NASDAQ CMPX opened at $6.47 on Thursday. The firm has a market cap of $1.15 billion, a P/E ratio of -14.38 and a beta of 1.46. Compass Therapeutics has a 1 year low of $1.33 and a 1 year high of $6.88. The firm’s 50 day moving average price is $5.74 and its 200 day moving average price is $4.57.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Cantor Fitzgerald started coverage on Compass Therapeutics in a research report on Wednesday, December 3rd. They issued an “overweight” rating for the company. Canaccord Genuity Group set a $13.00 price target on Compass Therapeutics in a research note on Wednesday, February 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Therapeutics in a research note on Wednesday, January 21st. Raymond James Financial reiterated an “outperform” rating and set a $9.00 price objective on shares of Compass Therapeutics in a report on Tuesday, January 6th. Finally, D. Boral Capital restated a “buy” rating and issued a $30.00 target price on shares of Compass Therapeutics in a report on Tuesday, January 6th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $13.36.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. XTX Topco Ltd grew its stake in Compass Therapeutics by 582.2% during the fourth quarter. XTX Topco Ltd now owns 115,634 shares of the company’s stock worth $621,000 after buying an additional 98,684 shares during the period. Ikarian Capital LLC acquired a new position in shares of Compass Therapeutics during the 4th quarter valued at $4,296,000. Virtus Investment Advisers LLC purchased a new stake in Compass Therapeutics during the 4th quarter worth $277,000. SummitTX Capital L.P. purchased a new stake in Compass Therapeutics during the 4th quarter worth $437,000. Finally, Suvretta Capital Management LLC increased its holdings in Compass Therapeutics by 0.6% in the 4th quarter. Suvretta Capital Management LLC now owns 14,182,379 shares of the company’s stock valued at $76,159,000 after purchasing an additional 81,220 shares in the last quarter. 68.43% of the stock is owned by institutional investors and hedge funds.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.